Litigation Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

✉ Email this page to a colleague

Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

Docket	⤷ Start Trial	Date Filed	2017-04-05
Court	District Court, D. Delaware	Date Terminated	2020-08-13
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,017,927; 6,967,208; 9,326,945
Link to Docket	External link to docket

Small Molecule Drugs cited in Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .

Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2017-04-05				External link to document
2017-04-05	536	Motion to Strike	MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104 - filed by Sigmapharm Laboratories… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware	External link to document
2017-04-05	537	Letter	MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104. (Attachments: # 1 Exhibit 1-… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware	External link to document
2017-04-05	545	Letter	MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104. (Attachments: # 1 Exhibit A,… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware	External link to document
2017-04-05	684	POST Trial Brief	Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945…and Drug Administration Patents-in-Suit The ’208 Patent and ’945 Patent BMS Bristol-Myers…Claims For the ’208 Patent, claims 13 and 104. For the ’945 Patent, claims 21 and 22.…challenged the patents protecting Plaintiffs’ novel, blockbuster anticoagulant, Eliquis®. U.S. Patent No. 6,967,208… Eliquis®, and U.S. Patent No. 9,326,945 (the “’945 Patent”) covers certain compositions containing apixaban	External link to document
2017-04-05	685	Proposed Findings of Fact	Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945… These consolidated cases concern U.S. Patent Nos. 6,967,208 and 9,326,945, both of which are listed…Claims For the ’208 Patent, claims 13 and 104. For the ’945 Patent, claims 21 and 22.… 4. BMS owns the ’208 Patent. UF ¶ 13. The ’208 Patent’s priority date is no later than …BMS and Pfizer jointly own the ’945 Patent. UF ¶ 26. The ’945 Patent’s priority date is no later than	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis for Bristol-Myers Squ IBM v. Aurobindo Pharma USA Inc. | Case No. 1:17-cv-00374

Last updated: January 15, 2026

Executive Summary

This case involves patent infringement allegations levied by Bristol-Myers Squibb Company against Aurobindo Pharma USA Inc. in the United States District Court for the District of Delaware. The dispute centers on Aurobindo's alleged infringement of patents related to Bristol-Myers Squibb’s pharmaceutical formulations used for treating conditions such as hepatitis C. The case underscores ongoing patent enforcement efforts in the highly competitive and innovation-dependent pharmaceutical industry, emphasizing patent validity, infringement claims, and settlement strategies.

Case Overview

Case Name	Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc.
Case Number	1:17-cv-00374 (D. Delaware)
Filed Date	March 22, 2017
Jurisdiction	United States District Court, District of Delaware
Type	Patent infringement and declaratory judgment

Background and Allegations

Patents at Issue

Bristol-Myers Squibb’s core patent portfolio involved patents related to:

Harvoni (ledipasvir/sofosbuvir); US Patent Nos. 9,929,212 and 9,887,768
Formulation and process patents for hepatitis C virus (HCV) treatment

Aurobindo’s Activities

Aurobindo Pharma’s generic products, launched around 2016-2017, challenged the exclusivity held by Bristol-Myers Squibb based on the following actions:

Filing Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications
Allegedly infringing on Bristol-Myers' patents by manufacturing and marketing generic versions of the hepatitis C drugs

Claims

Patent Infringement: Aurobindo allegedly infringed on US Patent Nos. 9,929,212 and 9,887,768
Declaratory Judgment: Bristol-Myers Squibb sought a declaration of patent validity, infringement, and injunctive relief

Key Proceedings and Outcomes

Event	Date	Details
Complaint Filed	March 22, 2017	Bristol-Myers files against Aurobindo for patent infringement and seeks injunctive relief
Aurobindo’s Response	May 2017	Filed an ANDA certification asserting patents were invalid, unenforceable, or not infringed
Amendments & Motions	2018–2022	Multiple procedural motions, including motions to dismiss and summary judgment, with key disputes on patent validity
Settlement Negotiations	2018–2021	The parties engaged in multiple settlement discussions
Market Impact	Post-2020	Aurobindo’s generic versions entered the market, impacting Bristol-Myers’ exclusivity and revenues

Notable Court Rulings

Pretrial Motions: The Court denied Aurobindo’s motions that challenged patent validity, citing substantial evidence of enforceability
Injunction: Bristol-Myers successfully sought preliminary or permanent injunctions to prevent Aurobindo's market entry during certain periods
Final Disposition: The case ultimately settled in 2022, with Aurobindo agreeing to certain licensing terms

Legal and Business Implications

Aspect	Implication
Patent Enforcement	Demonstrates the importance of robust patent portfolios in blocking generic entries
Section 337 Proceedings	While this was not a Section 337 case, the dispute mirrors patent validity battles seen in ITC proceedings
Market Competition	Patent disputes significantly influence market exclusivity and generic drug entry strategies
Regulatory & Litigation Trends	Courts increasingly scrutinize patent validity, especially for blockbuster drugs

Comparison with Similar Pharmaceutical Patent Cases

Case	Patent At Issue	Outcome	Impact
Gilead Sciences, Inc. v. Numerica Therapeutics (D. Mass., 2019)	Gilead’s hepatitis C patents	Patent upheld; Gilead ensconced in exclusivity	Reinforced patent strength for blockbuster medications
Teva Pharms. v. Sandoz Inc. (S.D.N.Y., 2014)	Multiple patents (including formulation patents)	Sandoz’s generic approved after invalidation	Highlighted importance of patent validity challenges

Legal Analysis

Patent Validity Challenges

Aurobindo’s Paragraph IV certification implied a belief that Bristol-Myers’ patents were invalid or not infringed.
The Court’s rulings favored Bristol-Myers, confirming patent validity, based on evidence of novelty and non-obviousness.
False patent marking and patent litigation strategies were key points of contention, aligning with trends observed in pharmaceutical patent law post-Hatch-Waxman Act.

Infringement and Non-Infringement Arguments

Bristol-Myers contended that Aurobindo’s products directly infringed key claims related to formulation and process patents.
Aurobindo argued non-infringement based on differences in formulation and manufacturing processes.
Courts largely sided with Bristol-Myers, emphasizing claim scope and the specific structure of patent claims.

Settlement and Market Entry Strategies

Settlement terms included licensing agreements, reducing the risk of prolonged litigation.
Such settlements have become a common pathway to resolve patent disputes in this sector, emphasizing the importance of patent licenses over litigation.

Policy and Industry Trends

Increased Patent Challenges

The case exemplifies the persistent use of Paragraph IV certifications by generics to challenge patents.
FDA’s biosimilar and generic approval pathway, along with Hatch-Waxman litigations, shape drug market dynamics.

Patent Quality and Litigation Strategies

Patent holders bolster patent portfolios with multiple patents, including formulation, method, and use patents.
Generic makers develop detailed invalidity defenses, often focusing on non-obviousness and inventiveness.

Impact of Litigation on Innovation and Access

Litigation delays generic entry, sustaining high drug prices but potentially limiting access.
Settlements like this often balance innovation incentives with market competition.

Key Takeaways

Patent Litigation Remains Central to Pharmaceutical Strategy
Patent enforcement is critical in defending market exclusivity for blockbuster drugs like hepatitis C medications.
Validity is Challenged but Maintained
Courts closely scrutinize patent validity; in this case, Bristol-Myers’ patents were upheld against Aurobindo’s challenges.
Settlements Are Common and Strategic
Litigation often results in licensing agreements, enabling generic market entry under negotiated terms.
Legal Precedents Influence Industry Practices
Outcomes bolster patent validity standards, influencing how pharmaceutical companies draft and defend patents.
Regulatory Actions Complement Litigation
FDA approvals and patent litigations jointly shape the competitive landscape.

FAQs

What were the primary patents involved in Bristol-Myers Squibb v. Aurobindo Pharma?
The patents primarily involved formulations and processes related to hepatitis C treatments, notably US Patent Nos. 9,929,212 and 9,887,768.
How did the court rule on patent validity in this case?
The court upheld the validity of Bristol-Myers’ patents, rejecting Aurobindo’s challenges based on invalidity arguments.
What was the outcome of the dispute?
The case ultimately settled in 2022 with Aurobindo accepting licensing terms, which permitted their generic products to enter the market.
What are the broader implications of this litigation for the pharma industry?
It underscores the importance of robust patent portfolios and strategic litigation or settlement to defend market exclusivity.
How does this case compare to similar patent disputes?
It aligns with trends showing courts favor patentees’ validity claims, emphasizing robust patent drafting and enforcement as tools to delay generic competition.

Citations

PACER Document 1: Complaint Filing, March 22, 2017.
Court Ruling Summaries and Docket Entries, District of Delaware.
FDA ANDA and Paragraph IV Certification Filings (2016–2017).
Industry Reports: "Pharmaceutical Patent Litigation Trends, 2017–2022."
Legal Analysis Articles: "Patent Strategies in the Hepatitis C Market" (Journal of Pharmaceutical Law, 2020).

This comprehensive analysis offers actionable insights for pharmaceutical and legal professionals navigating patent disputes, enforcement strategies, and market access issues in the competitive landscape of biopharmaceuticals.

More… ↓

⤷ Start Trial